(Total Views: 611)
Posted On: 11/26/2021 11:41:06 AM
Post# of 153995
Quote:
Driving the news: The drugmaker said molnupiravir reduced the risk of hospitalization or death for patients with mild or moderate COVID-19 by about 30%, based on a study of more than 1,400 adults. Last month, the company said the study showed about 50% efficacy, based on data from 775 patients.
Updated data shows Merck antiviral COVID pill less effective
(4)
(0)
